Arcion Therapeutics (Baltimore, MD) a clinical stage biotechnology company focused on the development of new, targeted treatments for severe pain treatment in diabetic neuropathy and post-herpetic neuralgia closed a $8.8M Series A financing. Participants include CMEA Ventures and InterWest Partners.

PainCeptor (Canada) a drug company focused on the treatment of chronic and acute pain raised a $20.8M Series B round. The deal was lead by Desjardins Venture Capital, CDP Capital, T2C2 Capital, Business Development Bank of Canada and Lothian Partners.

Horizon Therapeutics (Palo Alto, CA) a late stage biopharmaceutical company focused on development of drugs for pain relief has raised $15M in Series B funding. The deal was lead by Scale Venture Partners, and joined by return backers Sutter Hill Ventures and Pequot Ventures.